• Profile
Close

Rates of escalation to triple COPD therapy among incident users of LAMA and LABA/LAMA

Respiratory Medicine Apr 29, 2018

Hahn B, et al. - In this retrospective study, researchers sought to characterize chronic obstructive pulmonary disease (COPD) patients initiating treatment with the long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and the fixed-dose LAMA/long-acting &beta2-agonist (LABA) combination therapy umeclidinium/vilanterol (UMEC/VI). They also compared rates of escalation to triple therapy (TT, combining a LAMA, LABA, and inhaled corticosteroid) between patients receiving these therapies. Study participants were COPD patients enrolled in a US health insurance plan during 2013–2015 and newly initiated on TIO or UMEC/VI. In new TIO users vs in new UMEC/VI users, significantly higher rate of TT initiation were noted after propensity score matching. Overall, relative to patients receiving TIO, patients receiving UMEC/VI progressed to TT more slowly, and were at lower risk of progressing to TT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay